Baseline risk factors for relapse in HIV/HCV co-infected patients treated with PEG-IFN/RBV

被引：0
|
作者：
A. Rivero-Juarez
J. A. Mira
A. Camacho
K. Neukam
I. Perez-Camacho
A. Caruz
J. Macias
J. Torre-Cisneros
J. A. Pineda
A. Rivero
机构：
[1] Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC),Unidad de Enfermedades Infecciosas
[2] Hospital Universitario Reina Sofia,Unidad de Enfermedades Infecciosas
[3] Hospital Universitario Virgen de Valme,Departamento de Biología Molecular
[4] Hospital de Poniente,undefined
[5] Universidad de Jaen,undefined
来源：
Infection | 2013年 / 41卷
关键词：
HCV; HIV; End-of-treatment response; Viral relapse; Risk factors;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：21 / 26
页数：5
相关论文
共 50 条
  • [41] Inflammatory cells and apoptosis in HCV and co-infected HCV/HIV patients
    Petrovic, L.
    Rohan, S.
    Hayek, E.
    LIVER INTERNATIONAL, 2006, 26 : 74 - 74
  • [42] Comparison of therapeutic results on HCV and HCV/HIV co-infected patients
    Serra, J. E.
    Guzman, D.
    Velez, J.
    Pinto, P.
    Marques, N. M.
    da Cunha, J. G. Saraiva
    Melico-Silvestre, A.
    JOURNAL OF CLINICAL VIROLOGY, 2006, 36 : S144 - S144
  • [43] GENOME-WIDE SINGLE NUCLEOTIDE POLYMORPHISM ANALYSIS IDENTIFIES A UNIQUE CCL-5 HALPLOTYPE IN HIV/HCV CO-INFECTED NON-RESPONDERS TO PEGYLATED-INTERFERON (PEG-IFN) AND RIBAVIRIN (RBV) THERAPY
    Lempicki, Richard A.
    Schlaak, Joerg F.
    Masur, Henry
    Polis, Michael A.
    Kottilil, Shyam
    HEPATOLOGY, 2009, 50 (04) : 690A - 690A
  • [44] Modeling HCV viral kinetic response to PEG-IFN/ribavirin in HCV/HIV coinfected patients.
    Sherman, KE
    Horn, PS
    Rouster, SD
    Peters, MG
    Koziel, MJ
    Israel, B
    Chung, RT
    HEPATOLOGY, 2003, 38 (04) : 308A - 309A
  • [45] Probing inflammatory signaling pathways in IFN-alpha-treated, HIV/HCV co-infected patients using flow cytometry
    Alagbe, O
    Wang, XH
    Miller, AH
    NEUROPSYCHOPHARMACOLOGY, 2004, 29 : S86 - S87
  • [46] Erythropoictic response to anemia is decreased in patients infected with hepatitis C virus (HCV) receiving combination ribavirin and pegylated interferon (RBV/PEG-IFN) therapy
    Balan, V
    Wu, GY
    Muir, AJ
    Keeffe, EB
    Bowers, PJ
    GASTROENTEROLOGY, 2003, 124 (04) : A751 - A751
  • [47] Comparison of cognitive performance in HIV or HCV mono-infected and HIV–HCV co-infected patients
    N. Ciccarelli
    M. Fabbiani
    P. Grima
    K. Falasca
    M. Tana
    E. Baldonero
    M. Colafigli
    M. C. Silveri
    J. Vecchiet
    R. Cauda
    S. Di Giambenedetto
    Infection, 2013, 41 : 1103 - 1109
  • [48] Predictive Factors for Silibinin Monotherapy in Patients With Chronic Hepatitis C and Nonresponse to PEG-IFN/RBV Therapy
    Rutter, Karoline
    Stattermayer, Albert
    Reiberger, Thomas
    Aberle, Judith H.
    Zinober, Kerstin
    Scherzer, Thomas-Matthias
    Beinhardt, Sandra
    Holzmann, Heidemarie
    Steindl-Munda, Petra
    Hofer, Harald
    Ferenci, Peter
    GASTROENTEROLOGY, 2010, 138 (05) : S214 - S215
  • [49] PREDICTIVE FACTORS FOR SILIBININ MONOTHERAPY IN PATIENTS WITH CHRONIC HEPATITIS C AND NONRESPONSE TO PEG-IFN/RBV THERAPY
    Rutter, K.
    Staettermayer, A.
    Reiberger, T.
    Aberle, J.
    Zinober, K.
    Scherzer, T. -M.
    Beinhardt, S.
    Holzmann, H.
    Steindl-Munda, P.
    Hofer, H.
    Ferenci, P.
    JOURNAL OF HEPATOLOGY, 2010, 52 : S124 - S124
  • [50] LDLr genotype modifies the impact of IL28B on HCV viral kinetics after the first weeks of treatment with PEG-IFN/RBV in HIV/HCV patients
    Rivero-Juarez, Antonio
    Camacho, Angela
    Caruz, Antonio
    Neukam, Karin
    Gonzalez, Rafael
    Di Lello, Federico A.
    Perez-Camacho, Ines
    Mesa, Pilar
    Torre-Cisneros, Julian
    Pena, Jose
    Pineda, Juan A.
    Rivero, Antonio
    AIDS, 2012, 26 (08) : 1009 - 1015
12345